| Not Yet Recruiting | Low-Count Quantitative SPECT for Men Treated With Radium-223 NCT07221825 | Washington University School of Medicine | N/A |
| Recruiting | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enza NCT07028853 | Pfizer | Phase 3 |
| Recruiting | Investigation of Impact of AI on Prostate Cancer Workflow NCT07084779 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Hea NCT07109427 | Washington University School of Medicine | N/A |
| Completed | A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensi NCT07086651 | Pfizer | — |
| Recruiting | A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers NCT06363266 | St. Mary's Research Center, Canada | N/A |
| Active Not Recruiting | Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boo NCT05628363 | Washington University School of Medicine | N/A |
| Withdrawn | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NCT05191017 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid NCT05252390 | Nuvation Bio Inc. | Phase 1 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Recruiting | MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer NCT05241236 | Urological Research Network, LLC | — |
| Completed | I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). NCT03939689 | Progenics Pharmaceuticals, Inc. | Phase 2 |
| Completed | High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs NCT03653819 | Herlev and Gentofte Hospital | N/A |
| Active Not Recruiting | Proton Boost in Prostate Cancer NCT03564275 | University of Cincinnati | N/A |
| Completed | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostat NCT03392428 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 |
| Unknown | Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer NCT03960788 | University of Cincinnati | EARLY_Phase 1 |
| Unknown | Decision Impact Trial of the ExoDx Prostate (IntelliScore) NCT03235687 | Exosome Diagnostics, Inc. | N/A |
| Completed | Prostate Cancer Survivors and Exercise and Behavioral Counseling NCT03191968 | University of Illinois at Urbana-Champaign | Phase 2 |
| Completed | Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate NCT03124433 | Singapore General Hospital | Phase 2 |
| Unknown | MR-simulation in Radiotherapy for Prostate Cancer NCT03238170 | Guy's and St Thomas' NHS Foundation Trust | N/A |
| Completed | Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer NCT03285048 | Yale University | N/A |
| Completed | Urology of Virginia Case Series NCT03035487 | Exact Imaging | N/A |
| Terminated | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutam NCT02640534 | Swiss Cancer Institute | Phase 2 |
| Completed | Comparison Of DIR-MRI And DCE-MRI In Detection Of Prostate Cancer: A Pilot Study NCT02939456 | University Hospitals of North Midlands NHS Trust | N/A |
| Completed | European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up NCT04017325 | Steba Biotech S.A. | — |
| Completed | Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors NCT02957357 | Alliance Foundation Trials, LLC. | — |
| Completed | Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer NCT02578940 | Blue Earth Diagnostics | Phase 3 |
| Terminated | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel NCT02349386 | BHR Pharma, LLC | Phase 2 |
| Completed | The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects NCT02274350 | Herlev Hospital | — |
| Terminated | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer NCT02349139 | Asana BioSciences | Phase 1 |
| Unknown | Evaluation of the Accuracy of the Elastic Fusion MRI-ultrasound Obtained in Vivo by the Koelis™ System NCT02879851 | Hospices Civils de Lyon | — |
| Active Not Recruiting | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBA NCT02319837 | Pfizer | Phase 3 |
| Unknown | Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer NCT02334579 | Swedish Medical Center | N/A |
| Completed | Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultras NCT02079025 | Exact Imaging | N/A |
| Completed | PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Tra NCT04057859 | CMX Research | — |
| Completed | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer NCT02003924 | Pfizer | Phase 3 |
| Recruiting | MRI/Ultrasound Fusion Guided Prostate Cryotherapy NCT02381990 | Urological Research Network, LLC | — |
| Completed | Hemi-Ablative Prostate Brachytherapy NCT02632669 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Completed | Sipuleucel-T Manufacturing Demonstration Study NCT01477749 | Dendreon | Phase 2 |
| Completed | Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose NCT02212548 | Royal North Shore Hospital | N/A |
| Completed | North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) NCT02564120 | UNC Lineberger Comprehensive Cancer Center | — |
| Completed | Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer NCT01303705 | Providence Health & Services | Phase 1 |
| Completed | Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Abl NCT00970203 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Eligard Observational Registry for Patients With Prostate Cancer NCT00992251 | CMX Research | — |
| Completed | Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer NCT00844792 | University Health Network, Toronto | Phase 2 |
| Completed | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance NCT00744549 | University Health Network, Toronto | Phase 2 |
| Unknown | A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors NCT02225262 | Community Cancer Center, Normal, Illinois | N/A |
| Unknown | Multicentric Study Comparing Carcinological and Functional Results of Surgery NCT00502723 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution NCT00643994 | Accuray Incorporated | N/A |
| Completed | A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Ca NCT00564928 | Infinity Pharmaceuticals, Inc. | Phase 2 |
| Completed | CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry NCT00643617 | Accuray Incorporated | N/A |
| Completed | Vessel Sparing Prostate Radiation Therapy NCT02958787 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cance NCT01897207 | Cantonal Hospital of St. Gallen | Phase 1 / Phase 2 |
| Completed | A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Che NCT00257478 | Astellas Pharma Inc | Phase 2 |
| Approved For Marketing | Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study NCT02355054 | Washington University School of Medicine | — |